The proposed mechanisms of treatment-related thrombocytopenia include inhibition of proliferation of megakaryocytes from IFN-α [28]; and, less commonly, autoimmune reactions [29] and impaired TPO production [30]. This evidence concerns the gene TPO and Thrombocytopenia.